Health Care & Life Sciences » Pharmaceuticals | Karolinska Development AB

Karolinska Development AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
4,948.00
5,667.00
5,402.00
6,357.00
52,590.00
102,653
Unusual Expense
137,467.00
-
-
-
-
-
Pretax Income
157,315.00
377,560.00
1,054,673.00
216,832.00
179,595.00
30,510
Equity in Affiliates
-
1,745.00
-
-
-
-
Consolidated Net Income
157,315.00
375,815.00
1,054,673.00
216,832.00
179,595.00
30,510
Net Income
157,315.00
375,815.00
1,054,673.00
216,832.00
179,595.00
30,510
Net Income After Extraordinaries
157,315.00
375,815.00
1,054,673.00
216,832.00
179,595.00
30,510
Net Income Available to Common
157,315.00
375,815.00
1,054,673.00
216,832.00
179,595.00
30,510
EPS (Basic)
3.25
7.73
19.84
4.08
2.93
0.48
Basic Shares Outstanding
48,350.00
48,606.20
53,151.30
53,210.20
61,243.20
64,136.90
EPS (Diluted)
3.25
7.73
19.84
4.08
2.93
0.48
Diluted Shares Outstanding
48,350.00
48,606.20
53,151.30
53,210.20
61,300.50
64,136.90
Total Expense
-
383,842.00
1,060,298.00
224,248.00
127,029.00
79,224
Operating Income
-
378,175.00
1,054,896.00
217,891.00
179,619.00
23,429
Non-Operating Income (Expense)
5,887.00
615.00
223.00
1,059.00
24.00
7,081

About Karolinska Development AB

View Profile
Address
Tomtebodavägen 23A
Solna AB 171 65
Sweden
Employees -
Website http://www.karolinskadevelopment.com
Updated 07/08/2019
Karolinska Development AB engages in the investment in pharmaceutical business. It invests in companies that develop medical innovations, specialty care products and orphan drugs for patients suffering from life-threatening and serious debilitating conditions. Its funds are obtained from independent investors and shareholders by issuing and selling shares and interest-bearing instruments.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.